ライフサイエンスコーパス: heart

1 d hearts during ischemia (P < 0.05 vs. young hearts).

2 an emerging therapy for treating the failing heart.

3 ity to replenish the functional cells to the heart.

4 r 1 cytokine-mediated inflammatory damage in heart.

5 (i.e. Pnmt(+) cell derived cells) within the heart.

6 g either isoform of the gamma-subunit in the heart.

7 associated with decreased neutrophils in the heart.

8 n arrhythmia being found in the atria of the heart.

9 e 5.7 Gy for whole lung and 4.4 Gy for whole heart.

10 vitro and transplantation into the infarcted heart.

11 en-activated protein kinase signaling in the heart.

12 and with functional maturation of the entire heart.

13 C9 decreases Hsp20-associated AC activity in heart.

14 hich support cBIN1 release in MPs from human hearts.

15 nflammatory cytokines, compared to wild type hearts.

16 arcomeres from degradation in ncx1-deficient hearts.

17 cumulation of Ly6C(low) Mos/Mps in infarcted hearts.

18 TRPC6-deficient mouse hearts 1 week after transverse aortic constriction showe

19 In CTL hearts, 1.4% of myocytes were poorly synchronized with n

20 t increased lysine acetylation in Cpt2M(-/-) hearts 2.3-fold compared with littermate control mice fe

21 Domestication is at its heart an evolutionary process, and for many prehistorian

22 s defined by a focus of infection within the heart and is a feared disease across the field of cardio

23 ce in which Sco1 was specifically deleted in heart and striated muscle, respectively.

24 lls and their cell fate potentials in normal hearts and during cardiac remodeling following myocardia

25 These include kidney, heart, and lung candidates who are highly-allosensitized

26 Solitary kidney, liver, heart, and lung transplants performed between January 1,

27 organ-on-a-chip system, comprised of liver, heart, and lung, and highlight examples of inter-organ r

28 often place pressure and volume loads on the heart, and over time, these chronic loads can cause hear

29 levated Fgf21 mRNA and protein solely in the heart, and upregulation of FGF21-target genes involved i

30 gically and pathologically hypertrophied rat hearts, and correlated these marks with their associated

31 American College of Cardiology and American Heart Association (ACC/AHA) recommend lipid screening in

32 icular ejection fraction </=35% and New York Heart Association class II to III were randomly assigned

33 gned 8399 patients with chronic HF, New York Heart Association class II to IV symptoms, and a left ve

34 tomatic congestive heart failure of New York Heart Association class III or IV, confirmed by a cardio

35 Using multivariable analysis, New York Heart Association class III/IV, RVESRI, and log NT-proBN

36 t is typically not considered among New York Heart Association class IV (NYHA IV) heart failure patie

37 The CHA study (Chicago Heart Association Detection Project in Industry) is a lo

38 rtality included cardiac variables (New York Heart Association Functional Class III or IV, previous a

39 Using data from the American Heart Association Get With The Guidelines-Stroke Registr

40 e of American College of Cardiology/American Heart Association HF stages among older individuals in t

41 This American Heart Association presidential advisory on dietary fats

42 The American Heart Association recommends that children aged <2 y sho

43 This American Heart Association scientific statement reviews the scien

44 analyzed lncRNA expression profiles in mouse hearts at postnatal day (P) 1, P7 and P28 via microarray

45 Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a B

46 The neonatal mouse heart can regenerate, but only during the first week of

47 hospital was randomly assigned to switch to "HEART care," during which physicians calculated the HEAR

48 Activation of SGK1 in the heart causes a marked increase in both the peak and late

49 The S672R mutation in heart cell ion channels leads to low heart rates and arr

50 d mathematical modelling with experiments in heart cells from guinea pigs to determine how cellular e

51 ronary CT angiography performed with a whole-heart CT scanner.

52 f T. cruzi infection have been used to study heart damage in Chagas disease.

53 the fetal cerebral T2* in 28 fetuses without heart defects to that of 15 fetuses with major heart def

54 contribute to the pathogenesis of congenital heart defects, but it is unclear whether individual comm

55 naling and MET in the etiology of congenital heart defects.

56 art defects to that of 15 fetuses with major heart defects: transposition of the great arteries (n=7)

57 Furthermore, Sesn2-knockout hearts demonstrate a cardiac phenotype and response to i

58 rt revealed that the Nedd4 protein regulates heart development in Drosophila Larval fly hearts overex

59 MSCs and subcutaneous MSCs from LVD and sham hearts did not improve LV remodeling and function, cardi

60 length (TL) to be a risk factor for coronary heart disease (CHD), and recently the association was su

61 morbidity associated with complex congenital heart disease (CHD), while the underlying biological mec

62 ned by apoC-III are associated with coronary heart disease (CHD).

63 associated with type 2 diabetes and coronary heart disease (CHD).

64 model to predict outcomes in stable coronary heart disease (CHD).

65 whereas 172 suffered from a chronic ischemic heart disease (CIHD), 126 of whom underwent challenges.

66 32), but higher risks of death from coronary heart disease (HR: 1.45; 95% CI: 1.21 to 1.74), myocardi

67 The pathogenic role of ischemic heart disease (IHD) in heart failure (HF) with reduced e

68 irculatory disease (p = 0.014) and ischaemic heart disease (p = 0.003), possibly due to competing cau

69 acific experience a high burden of rheumatic heart disease (RHD).

70 in small series of patients with structural heart disease (SHD) and recurrent ventricular tachyarrhy

71 her enrolled 4726 participants with coronary heart disease and 3529 controls.

72 d as an independent risk factor for coronary heart disease and cardiovascular mortality.

73 In a patient with congenital heart disease and heterotaxy, a disorder of left-right p

74 f hypertension, diabetes mellitus, ischaemic heart disease and hyperlipidemia.

75 PRETATION: In Chinese patients with coronary heart disease and impaired glucose tolerance, acarbose d

76 Outcomes included cumulative CVD (coronary heart disease and stroke) deaths prevented or postponed

77 luding assessment of structural and residual heart disease before and after surgery, quantification o

78 dL, pravastatin reduced the risk of coronary heart disease by 27% (P=0.033) and major adverse cardiov

79 between miRNAs and their targetome in Chagas heart disease by integrating gene and microRNA expressio

80 incident CVD events, including 916 coronary heart disease cases, were reported.

81 yed echocardiographic characteristics of the heart disease condition, yet only aged HCM females displ

82 initial trial phase and the risk of coronary heart disease death, cardiovascular death, and all-cause

83 tic effects on the indexing (first) coronary heart disease event.

84 oronary arteries from patients with ischemic heart disease implying a role in human arterial disease.

85 predict progression to death after coronary heart disease is established.

86 rs, admission >/=14 days of life, congenital heart disease requiring surgical repair at <7 days of li

87 rts, carriers of CHIP had a risk of coronary heart disease that was 1.9 times as great as in noncarri

88 s and associated such presence with coronary heart disease using samples from four case-control studi

89 e of sudden cardiac arrest due to structural heart disease was uncommon during participation in compe

90 t the CXCR4 locus with the risk for coronary heart disease, along with CXCR4 transcript expression in

91 tudy (1986 to 2012) who were free of cancer, heart disease, and stroke at baseline.

92 ardial infarction or death owing to coronary heart disease, and stroke, defined as the first nonfatal

93 dations for patients with prevalent coronary heart disease, and we offer recommendations, when data a

94 Incident CVD, which combines coronary heart disease, defined as the first incident myocardial

95 The hazard ratios for incident coronary heart disease, stroke, and CVD associated with a 1-SD de

96 r various causes of death, including cancer, heart disease, stroke, respiratory disease, and infectio

97 Patients with complex congenital heart disease, who may have undergone previous palliativ

98 trial arrhythmia in patients with congenital heart disease, with a predominantly paroxysmal pattern.

99 died during follow-up, and 22 152 died from heart disease.

100 requently occur in the context of structural heart disease.

101 n 12% to 13% of patients with PH due to left heart disease.

102 pendent and causal risk factors for coronary heart disease.

103 ths per 100000 persons) to 4.2 (hypertensive heart disease: 4.3 vs 17.9 deaths per 100000 persons).

104 3 has been shown to protect against coronary heart disease; we identified APOC3 homozygous pLoF carri

105 .96; 95% CI, 1.07 to 8.21; P = .04) and mean heart dose (HR, 1.07/Gy; 95% CI, 1.02 to 1.13/Gy; P = .0

106 Heart doses were not associated with overall survival.

107 2 and AMPK upstream LKB1 is impaired in aged hearts during ischemia (P < 0.05 vs. young hearts).

108 amine was sufficient to reverse the observed heart dysfunction in the double knockout mice.

109 poxia exposure, we found that hypoxia caused heart dysfunction.

110 n is associated with worse outcomes in acute heart failure (AHF).

111 nthracycline chemotherapy is associated with heart failure (HF) among survivors of non-Hodgkin lympho

112 Although heart failure (HF) disproportionately affects older adul

113 dorff-perfused hearts from control (CTL) and heart failure (HF) mice (HF induced by transaortic const

114 ABSTRACT: Heart failure (HF) patients with preserved ejection frac

115 enic role of ischemic heart disease (IHD) in heart failure (HF) with reduced ejection fraction (HFrEF

116 ath, hospitalization, thromboembolic events, heart failure (HF), and AF progression.

117 -blockers increase survival in patients with heart failure (HF), the mechanisms behind this protectio

118 extensively studied in patients with chronic heart failure (HF), with only limited success.

119 promote cardiac fibrosis (CF) in nonischemic heart failure (HF).

120 mising therapeutic approach for treatment of heart failure (HF).

121 I) are independently associated with risk of heart failure (HF).

122 a are central tenets of patient education in heart failure (HF).

123 Here, in the International Congestive Heart Failure (INTER-CHF) study, we aimed to measure mor

124 ents had persisting symptoms compatible with heart failure (median of 13 [range 0-76] in the Minnesot

125 l strategies for Management of Patients with Heart failure [TRIUMPH]; NTR1893).

126 of patients discharged from a previous acute heart failure admission.

127 f cardiovascular events may be enhanced when heart failure and glucose intolerance coexist and may be

128 5) and in a pig model with features of human heart failure and preserved ejection fraction with stern

129 in the treatment of subsets of patients with heart failure and pulmonary hypertension.

130 initiated significantly later with comorbid heart failure and renal failure, with absence of fever o

131 cardial samples from patients with end-stage heart failure at time of transplant, with or without dia

132 had a higher rate of hospital admission for heart failure decompensation in follow-up (HR, 1.66; 95%

133 noninvasive telemonitoring in patients with heart failure does not reduce mortality or hospitalizati

134 al of 30% to 40% of patients with congestive heart failure eligible for cardiac resynchronization the

135 hospital quartile of ICU use for congestive heart failure had a sensitivity of 50-60% and specificit

136 Approximately half of patients with heart failure have preserved ejection fraction.

137 3; 95% CI: 0.07 to 0.75), total mortality or heart failure hospitalization (aHR: 0.32; 95% CI: 0.12 t

138 y end point or day-30 all-cause mortality or heart failure hospitalization rate differed between the

139 measure mortality at 1 year in patients with heart failure in Africa, China, India, the Middle East,

140 essed cardiac hypertrophy and progression to heart failure in both vitamin D deficient and normal mic

141 From 2002 to 2014, heart failure incidence (standardised by age and sex) de

142 ian of 4.1 years, surgery patients had lower heart failure incidence than lifestyle modification pati

143 promise to expand the use of pressure-guided heart failure management.

144 point was defined as symptomatic congestive heart failure of New York Heart Association class III or

145 essure to Improve Outcomes in NYHA Class III Heart Failure Patients [CHAMPION]; NCT00531661).

146 Forty consecutive heart failure patients underwent planar acquisition 4 h

147 d in improvement of patient health status in heart failure patients with low self-reported hrQoL, but

148 ew York Heart Association class IV (NYHA IV) heart failure patients.

149 ffects with respect to rescuing the cellular heart failure phenotype.

150 13 [range 0-76] in the Minnesota Living with Heart Failure Questionnaire) and cardiac limitation on e

151 sus 29 kg/m(2)), worse Minnesota Living With Heart Failure score (48 versus 40), higher median N-term

152 expertise from interventional cardiologists, heart failure specialists, cardiac surgeons, and cardiac

153 strain and Ea were associated with worsening heart failure symptoms at 1 year.

154 is probably due to immunosenescence, because heart failure was associated with increased senescent CD

155 point of death, transplant, or admission for heart failure was reached in 88 patients.

156 aptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management [SECRET

157 METHODS AND We randomized 12 subjects with heart failure with preserved ejection fraction to oral K

158 In heart failure with preserved ejection fraction, patients

159 s, are under investigation for patients with heart failure with reduced left ventricular ejection fra

160 l strategies for Management of Patients with Heart failure) clinical cohort study, 496 patients with

161 Impact on Global Mortality and Morbidity in Heart Failure) trial randomly assigned 8399 patients wit

162 lar events (CVEs) including 281 (23.8%) with heart failure, 109 (9.2%) with atrial fibrillation, 89 (

163 A), and cBIN1 level decreased in humans with heart failure, a condition with reduced cardiac muscle c

164 530 771, and 1 125 231 hospitalizations for heart failure, acute myocardial infarction, and pneumoni

165 high risk of cardiovascular disease, stroke, heart failure, and atrial fibrillation.

166 Older age, congestive heart failure, and greater left ventricular dilation at

167 atal or nonfatal stroke, hospitalization for heart failure, and hospitalization for acute coronary sy

168 CM but for both groups older age, congestive heart failure, and increased left ventricular end-systol

169 Incident CVD included CHD, stroke, heart failure, and peripheral arterial disease.

170 onal Class III or IV, previous admission for heart failure, and valve disease) and non-cardiac variab

171 hetic stimulation have been reported in left heart failure, but whether it would be beneficial for pu

172 RATIONALE: In patients with chronic heart failure, daytime oscillatory breathing at rest is

173 safety endpoint were age, anemia, congestive heart failure, multivessel disease, number of stents imp

174 er risk of dying from myocardial infarction, heart failure, or stroke, respectively, than members of

175 In human heart failure, Ser199 (equivalent to Ser200 in mouse) of

176 death, nonfatal myocardial infarction [MI], heart failure, stroke, transient ischemic attack, periph

177 MACE, including cardiovascular mortality and heart failure.

178 diseases, including cardiac hypertrophy and heart failure.

179 ion in t-tubule organization and accelerated heart failure.

180 nfarction, stroke, or hospital admission for heart failure.

181 and over time, these chronic loads can cause heart failure.

182 normalities, including pericardial edema and heart failure.

183 ht further improve outcomes in patients with heart failure.

184 of respiratory and autonomic dysfunction in heart failure.

185 ive hypertrophic cardiomyopathy and advanced heart failure.

186 ardiomyopathy (DCM) is an important cause of heart failure.

187 l hypertension, obstructive sleep apnoea and heart failure.

188 lic target in a number of diseases including heart failure.

189 components of arsenic species in the Strong Heart Family Study (SHFS).

190 ment with crenolanib attenuated the skin and heart fibrosis.

191 In the heart, fibrosis causes mechanical and electrical dysfunc

192 companied by the expression of the secondary heart field marker, Islet1.

193 d by increased ratio of right- to left-sided heart filling pressures (0.64+/-0.17 versus 0.56+/-0.19

194 ion is critical for our understanding of how heart formation is initiated during embryonic developmen

195 DS AND We used isolated Langendorff-perfused hearts from control (CTL) and heart failure (HF) mice (H

196 t Tln1 can substitute for Tln2 in preserving heart function, but that loss of all Tln forms from the

197 utoradiography to determine that the failing heart has 30% lower SCN5A levels - the first evidence o

198 ine palmitoyl transferase I in normal rodent hearts has been shown to recapitulate the reduced fat ox

199 Conversely, Snrk knockout mouse hearts have increased glucose and palmitate oxidation an

200 mic stress that is similar to wild-type aged hearts (i.e., impaired ischemic AMPK activation and high

201 in defined functional lesions in the larval heart, implicating mechanical signaling and MET in the e

202 formation of craniofacial cartilage and the heart in developing zebrafish.

203 ctivation of the ERK pathway in vitro and in hearts in vivo.

204 ry of the progenitor cells into neonatal rat hearts, in vivo incubation and analysis.

205 Imaging in whole rat hearts indicated mitochondrial network formation and fus

206 m and that electrical propagation across the heart is facilitated in later gestation.

207 (cAMP) is physiologically beneficial in the heart, it largely contributes to cardiac disease progres

208 of microtissues derived from normal organs (heart, kidney) were relatively consistent when comparing

209 anced capillary density and maturation in db hearts less efficiently than in wt hearts, similar to co

210 789 Marfan patients enrolled in the National Heart, Lung, and Blood Institute GenTAC (Genetically Tri

211 Although the National Heart, Lung, and Blood Institute increased funding of ca

212 The National Institutes of Health/National Heart, Lung, and Blood Institute Pediatric Heart Network

213 hildren with FDCM or IDCM using the National Heart, Lung, and Blood Institute-funded Pediatric Cardio

214 c dysfunction, evidenced by a 5-fold greater heart mass, 60-90% reduction in blood ejection fraction

215 and glucocorticoid hormones are critical for heart maturation.

216 ment of pulmonary circulation, the ancestral heart may have been remodelled coincidently with, or acc

217 In a previously established Drosophila heart model for long-term hypoxia exposure, we found tha

218 ature based on whether normal or failing rat heart models were used.

219 a model GRN for the major gene batteries in heart morphogenesis.

220 rrhythmogenic cardiomyopathy is an inherited heart muscle disorder, predisposing to sudden cardiac de

221 ABSTRACT: Contraction of heart muscle is triggered by a transient rise in intrace

222 ion, but that loss of all Tln forms from the heart-muscle cell leads to myocyte instability and a dil

223 tetralogy of Fallot (n=1), hypoplastic right heart (n=1), and common arterial trunk (n=1).

224 l Heart, Lung, and Blood Institute Pediatric Heart Network Single Ventricle Reconstruction Trial publ

225 istent with empirical observations is at the heart of (applied) science and engineering.

226 with unique non-covalent interactions at the heart of each process.

227 hy the making and breaking of RBCs is at the heart of iron physiology, providing an ideal context to

228 Oocyte defects lie at the heart of some forms of infertility and could potentially

229 At the heart of these devices is the internal motion of electro

230 demonstrate that Cx43 is dysregulated in the hearts of HIV-infected individuals.

231 and microRNA expression profiling data from hearts of T. cruzi infected mice.

232 s heart development in Drosophila Larval fly hearts overexpressing miR-1 have profound defects in act

233 A heart rate <70 beats/min was also associated with a lowe

234 tasks (METs; 11.6 vs 11.7; P = .80), maximum heart rate (174 vs 175 beats/min; P = .41), and heart ra

235 ous Cx36 KO mice revealed higher variance in heart rate and blood pressure during rest and activity c

236 system testing revealed no abnormalities in heart rate and blood pressure variability however the sy

237 Changes in heart rate and the peak high frequency were correlated w

238 We meta-analysed heart rate association results from 104 452 European-anc

239 rt rate (174 vs 175 beats/min; P = .41), and heart rate at 2 minutes recovery (44 vs 43 beats/min; P

240 ith less heat discomfort, but did not affect heart rate differently compared with iopromide 300.

241 ur results reveal that in mammals, for which heart rate is a key determinant of cardiac energy demand

242 Increased resting heart rate is associated with worse outcomes in studies

243 informatics methods.We discovered five novel heart rate loci, and one new independent low-frequency n

244 ncy non-synonymous variant in an established heart rate locus (KIAA1755).

245 A low heart rate may be associated with higher AF risk.

246 length, body weight, body surface area, and heart rate on PAAT were investigated.

247 s-over-time temperature, blood pressure, and heart rate outcomes were also significantly lower at 2 h

248 ndogenous phosphodiesterase 2 contributes to heart rate regulation.

249 vary cortisol (hypothalamic pituitary axis), heart rate variability (sympathetic adrenal medullary sy

250 planchnic SNA (SSNA), arterial pressure, and heart rate via projections to the paraventricular nucleu

251 infections, and changes in body temperature, heart rate, and minute ventilation.

252 ange of cardiovascular parameters, including heart rate, arterial pressures, and body temperature.

253 ly assigned to HIIT at 90% to 95% of maximal heart rate, MCT at 60% to 70% of maximal heart rate, or

254 mal heart rate, MCT at 60% to 70% of maximal heart rate, or RRE.

255 8) showed more eye-blink reflexes and larger heart rate, skin conductance, and pupil area responses t

256 he first evidence of miR control of HCN4 and heart rate.

257 ing them unsuitable for applications such as heart-rate monitoring, which require a much lower pressu

258 tion in heart cell ion channels leads to low heart rates and arrhythmia by an unknown route.

259 We studied a validation cohort of 98 heart recipients transplanted in Edmonton, AB, Canada, i

260 rdiomyocyte polyploidization and compromised heart regeneration.

261 exhibits heat-shock (HS) inducible impaired heart regeneration.

262 ells (hPSCs) has generated opportunities for heart repair, disease modeling, and drug development.

263 se Nedd4 Analysis of embryonic and adult fly heart revealed that the Nedd4 protein regulates heart de

264 prepared by representatives of the European Heart Rhythm Association, Heart Rhythm Society, Asia-Pac

265 who were evaluated in Mayo Clinic's Genetic Heart Rhythm Clinic from January 1999 to December 2015.

266 ontrast Medium on Coronary Opacification and Heart Rhythm in Coronary CT Angiography, or IsoCOR, tria

267 ociation, Heart Rhythm Society, Asia-Pacific Heart Rhythm Society, and Sociedad Latinoamericana de Es

268 es of the European Heart Rhythm Association, Heart Rhythm Society, Asia-Pacific Heart Rhythm Society,

269 The HEART score risk stratification tool that merges troponi

270 are," during which physicians calculated the HEART score to guide patient management.

271 (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Ou

272 T cells isolated from TAC-treated hearts show enhanced production of proinflammatory cytok

273 Colon ascendens stent peritonitis hearts showed a significant increase in oxidation-depend

274 In GS-967-treated hearts, significantly more spontaneous termination of in

275 ion in db hearts less efficiently than in wt hearts, similar to collateral growth.

276 In participants in the Jackson Heart Study, a community-based observational study of ca

277 helial growth factor in Hyal2(-/-) embryonic hearts, suggest that HYAL2 is important to inhibit endot

278 n tissue asymmetry and growth that helps our hearts take shape.

279 that humans might literally 'listen to their heart' to guide their altruistic behavior.

280 Here we report the first in-depth survey of heart transcriptome variation using RNA-sequencing in 97

281 establishing and directing the first Swedish heart transplant program.

282 prospective clinical study including healthy heart transplant recipients 6 months to 25 years of age

283 ssociated with an increased risk of death or heart transplantation (all Ps<0.001).

284 Young adult heart transplantation (HTx) recipients experience high m

285 Instead, referral for heart transplantation may offer their best chance at lon

286 Heart transplantation recipients aged 2 to 40 years, tra

287 Computational modelling of the heart tube during development reveals the interplay betw

288 ntraction drive formation of the foregut and heart tube in the early chick embryo.

289 134 genes were tested in the Drosophila heart using RNAi-based gene silencing.

290 The CENTERA transcatheter heart valve (THV) is a low-profile, self-expanding nitin

291 mm; P<0.0001), and greater total epicardial heart volume (945 mL [831-1105 mL] versus 797 mL [643-97

292 The increase in heart volumes in obese HFpEF was associated with greater

293 onia (1,100-3,000 MBq) was injected into the heart wall insert of an anthropomorphic torso phantom.

294 cultures of several cell types found in the heart, we delineate the Wnt signaling apparatus supporti

295 Explants from healthy and failing human hearts were compared using radiocaine autoradiography to

296 re activated to a greater extent in perfused hearts when the LV performs pressure-volume work.

297 In hearts where electrocardiogram T waves involve a well-de

298 ine a new paradigm of gene regulation in the heart, where controlled changes in poly(A) tail length i

299 assive stiffness was a common feature in all hearts with DCM-associated mutations and may be causativ

300 organ transplants (31 kidney, 14 liver, four heart), with only one case of TMAT, which occurred in a